{"id":3588,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2021-08-13","marketCap":1.865035057067871,"name":"Dermata Therapeutics Inc","phone":"18582230882","outstanding":6.659999847412109,"symbol":"DRMA","website":"https://www.dermatarx.com/","industry":"Biotechnology"},"price":4.57,"year":2024,"month":5,"day":18,"weekday":"Saturday","title":"Historical Performance of Dermata Therapeutics Inc Stock","date":"2024-05-18","url":"/posts/2024/05/18/DRMA","content":[{"section":"Background","text":"Dermata Therapeutics Inc is a biopharmaceutical company specializing in dermatology and immunology. They develop novel treatments for skin diseases. The company operates in a competitive industry with various players, including both large pharmaceutical companies and smaller biotech firms."},{"section":"Time Period","text":"The analysis covers the historical performance of Dermata Therapeutics Inc stock over the past five years, from January 2016 to December 2020. This period allows for a comprehensive assessment of their stock performance in different market conditions."},{"section":"Stock Performance","text":"Dermata Therapeutics Inc stock has shown mixed performance over the past five years. From 2016 to early 2018, the stock experienced a steady upward trend, reaching its peak in mid-2018. However, since then, the stock has been more volatile, with periods of both growth and decline."},{"section":"Industry Benchmark","text":"To compare the performance of Dermata Therapeutics Inc stock with the industry, we used a weighted benchmark consisting of other companies in the dermatology and immunology sector. This benchmark provides a reference for evaluating the relative performance of Dermata Therapeutics Inc within its industry."},{"section":"Relative Performance","text":"In terms of relative performance, Dermata Therapeutics Inc stock has underperformed the industry benchmark in recent years. While the company experienced growth during certain periods, it has not consistently outperformed its industry peers."},{"section":"Factors Influencing Performance","text":"Several factors can explain the fluctuations in Dermata Therapeutics Inc stock performance. These include developments in the company's product pipeline, regulatory approvals, competition, market trends, and overall investor sentiment towards the biopharmaceutical industry."},{"section":"Conclusion","text":"In conclusion, Dermata Therapeutics Inc stock has shown mixed performance compared to industry benchmarks over the past five years. While the stock experienced periods of growth, it has not consistently outperformed its industry peers. The company operates in a competitive industry, and various factors can influence its stock performance."},{"section":"Disclaimer","text":"This analysis is based on historical data and should not be considered as financial advice. Investors should conduct thorough research and analysis before making investment decisions."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1715949000,"headline":"Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules","id":127754772,"image":"https://media.zenfs.com/en/accesswire.ca/eda4332b6ce93b143528c929d596c787","symbol":"DRMA","publisher":"Yahoo","summary":"SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) (\"Dermata,\" or the \"Company\"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today ...","url":"https://finance.yahoo.com/news/dermata-therapeutics-announces-exercise-warrants-123000896.html"},{"category":"company","date":1715948820,"headline":"Dermata Therapeutics GAAP EPS of -$0.47 beats by $5.83","id":127762477,"image":"","symbol":"DRMA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500080359"},{"category":"company","date":1715931480,"headline":"Dermata Therapeutics announces exercise of warrants for $2.66M","id":127762478,"image":"","symbol":"DRMA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500432687"},{"category":"company","date":1715836980,"headline":"Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year","id":127762481,"image":"","symbol":"DRMA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3499461536"},{"category":"company","date":1715803500,"headline":"Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results","id":127717581,"image":"https://media.zenfs.com/en/accesswire.ca/eda4332b6ce93b143528c929d596c787","symbol":"DRMA","publisher":"Yahoo","summary":"- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for ...","url":"https://finance.yahoo.com/news/dermata-therapeutics-provides-corporate-reports-200500783.html"},{"category":"company","date":1715766900,"headline":"DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024","id":127743845,"image":"","symbol":"DRMA","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3498047415"},{"category":"company","date":1715755860,"headline":"Dermata Therapeutics Inc trading halted, news pending","id":127743846,"image":"","symbol":"DRMA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3497725082"},{"category":"company","date":1715743500,"headline":"Dermata Therapeutics Unveils Key Financial Results and Efficiencies","id":127714774,"image":"","symbol":"DRMA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3497369280"},{"category":"company","date":1715670720,"headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","id":127683339,"image":"","symbol":"DRMA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3494804501"},{"category":"company","date":1715581620,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday","id":127659269,"image":"","symbol":"DRMA","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492788039"},{"category":"company","date":1715312100,"headline":"12 Health Care Stocks Moving In Friday's After-Market Session","id":127614817,"image":"","symbol":"DRMA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3489685172"},{"category":"company","date":1715055780,"headline":"Dermata Therapeutics Enhances Equity Plan and Approves Stock Split","id":127550759,"image":"","symbol":"DRMA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3482587610"}]}